Opendata, web and dolomites

HAIKU

A breakthrough alternative to antibiotics for preventing and curing infectious diseases at Intensive Care Units

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HAIKU project word cloud

Explore the words cloud of the HAIKU project. It provides you a very rough idea of what is the project "HAIKU" about.

irr    company    drug    mission    worldwide    800    market    develops    jobs    01    healthcare    pharma    million    1000    therapeutics    portfolio    social    ebitda    newly    curative    infectious    protection    stays    companies    patients    antibodies    addressable    21    risked    inhibitory    preventive    price    resistant    15    treatment    diseases    critical    preventing    benefit    mortality    therapy    13    freeing    resistance    public    sales    56    removing    prolonged    days    acquired    class    licensed    hospital    lives    risk    medicines    families    care    generating    150    2026    molecule    beds    line    consist    infectivity    de    multiple    icus    remab    clinical    gram    antibiotics    275    complete    units    natural    created    royalties    trials    finalise    group    rate    share    first    intensive    morbidity    bacteria    14    infections    gt    ph2       23    biotech    icu    ra    discount    net    antimicrobial    cumulative    curing    competitors    admitted    private    240    therapies    10    negative    reduce    amr    removal    total   

Project "HAIKU" data sheet

The following table provides information about the project.

Coordinator
REMAB THERAPEUTICS SL 

Organization address
address: C FEIXA LLARGA SN EDIFICIO BIOPOL OFFICE 3
city: HOSPITALET DE LLOBREGAT
postcode: 8907
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website https://remabtx.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    REMAB THERAPEUTICS SL ES (HOSPITALET DE LLOBREGAT) coordinator 50˙000.00

Map

 Project objective

Hospital-acquired infections are a major cause of morbidity, mortality and costs in Intensive care units (ICUs) worldwide. The most critical infectious group consist of Gram-negative bacteria that are resistant to multiple antibiotics.

We have developed RA-01, a novel drug product and a first line therapy for preventing and curing infectious diseases at ICUs based on the removal of inhibitory antibodies, which are used by bacteria to facilitate their infectivity. This new drug allows an immediate protection to patients admitted to ICU without generating antimicrobial resistance (AMR).

RA-01 will reduce public/private healthcare systems costs and improve a social benefit by freeing up hospital beds: €9,150 reduction in treatment costs, 7 days less at ICU and €15 k reduction in ICU costs.

Currently, our competitors are focused on new antibiotics and antibodies, so there are no other companies working in the removing of specific antibodies as a preventive and curative method for infectious diseases. The total potential market is estimated to be >13 million patients/year. From this market, will be target ICU patients at risk for prolonged stays: >4 million patients.

RemAb Therapeutics is a biotech company that develops a novel class of medicines by removing natural specific antibodies. Our mission is to advance our portfolio of therapies to clinical trials and improve the lives of patients and families affected by infectious diseases. Our drug molecule will be developed and de-risked through clinical trials-Ph2 and then licensed to pharma companies, to finalise their development and bring them to the market

By 2026 we expect to reach: a) 14% royalties’ rate on net sales with a RA-01 price to healthcare systems of €800-1000 (complete treatment); b) Total addressable market growing up to about €275 m; c) Net present value of €21.4 m (10% discount rate) and an IRR of 56%; d) Cumulative EBITDA over €23 m; e) 6% market share (240,000 patients); f) 15 newly created jobs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HAIKU" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HAIKU" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More